Name | Title | Contact Details |
---|
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera`s European operations are conducted from London by its subsidiary, Alimera Sciences Limited.
For pharmaceutical manufacturers and healthcare providers, AmerisourceBergen Specialty Group is an essential business partner.
Valcour Strategic Group is a Peru, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
P.E.C.S. is a Canovanas, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.